Erenumab: a monoclonal antibody for migraine prophylaxis

Abstract

Erenumab (Aimovig) is a monoclonal antibody targeting the calcitonin gene‐related peptide (CGRP) receptor that has been licensed for the prophylaxis of migraine in adults who have at least four migraine days per month. This article discusses its efficacy, adverse effects and place in therapy.